Exelixis | EXEL - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
Acadia Pharmaceuticals USD 279.64M 36.37M 2026-06
Agios Pharmaceuticals USD 19.43M 1.34M 2026-03
Akebia Therapeutics USD 47.28M 1.7M 2025-12
Amgen USD 5.87B 1.02B 2026-03
AstraZeneca USD 12.86B 251M 2026-06
Bayer EUR 6.33B 1.84B 2026-06
BioMarin Pharmaceutical USD 713.42M 142.21M 2026-06
Bristol-Myers Squibb USD 9.26B 1.19B 2026-06
Cytokinetics USD 23.03M 3.84M 2026-06
Eisai JPY 183.24B 29.83B 2026-06
Eli Lilly USD 16.22B 301.7M 2026-03
Exelixis USD 608.03M 17.17M 2026-06
Genmab DKK 1.07B 240M 2026-06
Glaxosmithkline GBP 5.75B 2.99B 2026-03
Incyte USD 1.57B 400.89M 2026-06
Ionis Pharmaceuticals USD 265M 22M 2026-06
MacroGenics USD 11.24M 19.87M 2026-03
Merck USD 12.09B 1.24B 2026-03
Moderna USD -566M 792M 2026-03
Nektar Therapeutics USD 10.86M 10.95M 2026-03
Neurocrine Biosciences USD 800.7M 12.8M 2026-03
Novartis USD 11.24B 1.18B 2026-06
Pfizer USD -248M 11.29B 2026-06
Puma Biotechnology USD 20.32M 24.85M 2024-09
Sanofi EUR 8.11B 343M 2026-03
Takeda JPY 813.22B 124.39B 2026-06
Ultragenyx Pharmaceutical USD 180M 74M 2026-06
Xencor USD 51.22M 46.7M 2026-06